Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Boehringer Ingelheim

Clinicaltrial registered9 Nov 2026

Boehringer Ingelheim

9 Nov 2026: Trial registered · A Study to Test Whether BI 3810477 Helps People With Idiopathic Pulmonary Fibrosis When Taken With or Without Standard Treatment. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
9 Nov 2026
Title
A Study to Test Whether BI 3810477 Helps People With Idiopathic Pulmonary Fibrosis When Taken With or Without Standard Treatment
Conditions
Idiopathic Pulmonary Fibrosis
Phase
Phase 2
Study Type
Interventional
Status
Not Yet Recruiting
Countries
United States, Belgium, Finland, Germany, Japan, Mexico, South Korea, Spain, United Kingdom
Country
United States
Reference
NCT07926321
Location
United States, Belgium, Finland
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Boehringer Ingelheim

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

Across AOS Research

Other records for Boehringer Ingelheim in our registers.

More from United States

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.